서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 36 of 36

Issue DateTitle / Author(s) / CitationFileAltmetrics
2006-07
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy
DOI
2006-11
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients
DOI
2007-05
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer
DOI
2007-10
Palliative chemotherapy for pulmonary pleomorphic carcinoma
DOI
2008-06
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
DOI
2008-07
Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment
DOI
2009-08
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
DOI
2010-03
Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer
DOI
2011-04
EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma
DOI
2011-05
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma Suggestion for an Effective Screening Strategy for These Tumors
DOI
2011-09
Anaplastic Lymphoma Kinase Translocation A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
DOI
2012-07
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer
DOI
2012-08
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
DOI
2012-08
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation
DOI
2013-01
Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer
DOI
2013-03
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma
DOI
2013-04
Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
DOI
2013-07
Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib
DOI
2013-08
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer

Lee, Eunyoung; Keam, Bhumsuk; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog

Journal of Thoracic Oncology, Vol.8 No.8, pp.1069-1074

DOI
2013-09
How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
view fileDOI
2013-11
Clinicopathologic Analysis of ROS1-Rearranged Non-Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm
DOI
2014-03
Clinical Significance of Downstaging in Patients With Limited-Disease Small-Cell Lung Cancer
DOI
2014-07
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HIVI30181A, in Patients with Advanced Solid Cancer
DOI
2014-08
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

Keam, Bhumsuk; Kim, Dong-Wan; Park, Jin Hyun; Lee, Jeong-Ok; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog

International Journal of Clinical Oncology, Vol.19 No.4, pp.594-600

DOI
2014-10
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
view fileDOI
2014-12
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer

Sim, Sung Hoon; Keam, Bhumsuk; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog

Journal of Cancer Research and Clinical Oncology, Vol.140 No.12, pp.2135-2142

DOI
2015-08
Total lesion glycolysis in positron emission tomography can predict gefitinib outcomes in non-small-cell lung cancer with activating EGFR mutation
DOI
2015-09
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
DOI
2015-12
Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor
DOI
2016-02
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
view fileDOI
2016-07
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer
DOI
2017-09
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
DOI
2019-01
Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients
DOI
2021-03
Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice
DOI
2021-06
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
DOI
2024
Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer
DOI
1